On September 16, 2026, RBC Capital initiated coverage of Solid Biosciences (NASDAQGS:SLDB) with an “Outperform” recommendation. This followed a decline in the stock price, which closed at $8.37 on September 15, reflecting a 15.71% drop from $9.93 on September 8. Over the previous month, the stock’s price decreased by 9.02% from a close of $9.20 on August 14, 2026.
The current consensus target for Solid Biosciences stands at $19.38, indicating a potential upside of 131.54% from the recent closing price. As of September 1, 2026, analyst recommendations included 8 strong buys, 10 buys, and 1 hold, with an overall positive recommendation rate of 94.7%.
Solid Biosciences reported earnings on August 6, 2026, with an actual EPS of -0.38, compared to an estimated EPS of -0.4776, and no reported revenue. The company is based in Charlestown, Massachusetts.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
